Ovid Therapeutics Inc. (OVID) Tops Q4 EPS by 22c

Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q4 EPS of $0.00, $0.22 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $140 thousand versus the consensus estimate of $8.62 million.

For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Stifel Starts Victrex Plc. (VCT:LN) (VTXPF) at Buy
• FirstCash to acquire UK pawn operator Ramsdens for £206 million